|
Biocon Ltd spurts 2.76%, rises for fifth straight session> |
|
Biocon Ltd spurts 3.7%, gains for third straight session> |
|
Biocon Pharma receives Health Canada approval for micafungin for injection USP 50 mg and 100 mg> |
|
Board of Biocon recommends final dividend> |
|
Biocon consolidated net profit declines 63.45% in the March 2026 quarter> |
|
Biocon posts PAT of Rs 126 crore in Q4 FY26; EBIDTA margin stands at 23%> |
|
Biocon Ltd soars 1.16%, gains for fifth straight session> |
|
Biocon Ltd soars 3.22%> |
|
Biocon to declare Quarterly Results> |
|
Biocon receives Health Canada approval for two biosimilars - Bosaya™ and Vezuo™> |